Pfizer Inc
Research Pfizer Inc (PFE) on Bullrun: valuation model: 10.2% undervalued, market cap USD 138.90B, P/E 18.7, dividend yield 7.1%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerPFE
- ExchangeNYSE
- CountryUnited States
- SectorHealthcare
- IndustryDrug Manufacturers-General
- CurrencyUSD
- Valuation signal10.2% undervalued
- Market capUSD 138.90B
- P/E18.7
- Dividend yield7.1%
- Financial periodFY2025
- RevenueUSD 62.58B
- Revenue growth-1.6%
- Net incomeUSD 7.77B
- Free cash flowUSD 9.08B
- Gross margin74.3%
Valuation Snapshot
Bullrun's latest valuation model marks Pfizer Inc as 10.2% undervalued; latest market cap is USD 138.90B; P/E is 18.7; dividend yield is 7.1%.
About Pfizer Inc
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands;
Frequently asked questions
Is Pfizer Inc overvalued or undervalued?
Bullrun's valuation model currently marks Pfizer Inc as 10.2% undervalued.
What is Pfizer Inc's market cap?
Pfizer Inc's market capitalization is USD 138.90B.
What is Pfizer Inc's P/E ratio?
Pfizer Inc's price-to-earnings (P/E) ratio is 18.7.
Does Pfizer Inc pay a dividend?
Pfizer Inc has a dividend yield of 7.1%.
What does Pfizer Inc do?
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.